RSL3: Potent GPX4 Inhibitor for Ferroptosis Induction in Cancer Research

Executive Summary: RSL3 is a small molecule inhibitor of glutathione peroxidase 4 (GPX4), a critical regulator of oxidative stress and lipid peroxidation in mammalian cells (Ghoochani et al., 2021). By inhibiting GPX4, RSL3 induces ferroptosis, an iron-dependent, non-apoptotic form of programmed cell death (APExBIO, Product B6095). RSL3 is particularly effective in cancer cells harboring oncogenic RAS mutations, where it demonstrates synthetic lethality at nanomolar concentrations . In vivo, RSL3 significantly reduces tumor volume in xenografted mice without observable toxicity up to 400 mg/kg . The compound is widely used as a research tool to dissect ferroptosis signaling and exploit redox vulnerabilities in cancer biology (see also).

Biological Rationale

Ferroptosis is a regulated, iron-dependent cell death mechanism distinguished by accumulation of lipid peroxides and reactive oxygen species (ROS) . GPX4 is a selenoenzyme that reduces lipid hydroperoxides to non-toxic lipid alcohols, thereby suppressing ferroptosis and maintaining redox homeostasis. Cancer cells, especially those with oncogenic RAS mutations or in treatment-resistant states, often upregulate antioxidant defenses such as GPX4, rendering them selectively vulnerable to GPX4 inhibition (contrast: systems biology perspective). By targeting GPX4 with RSL3, researchers can induce ferroptosis and overcome resistance mechanisms in diverse tumor models.

Mechanism of Action of RSL3 (glutathione peroxidase 4 inhibitor)

RSL3 acts by covalently binding to the active site selenocysteine of GPX4, irreversibly inhibiting its peroxidase activity (APExBIO). This inhibition prevents the reduction of lipid hydroperoxides, leading to accumulation of toxic lipid ROS. The elevated ROS levels result in oxidative damage to cellular membranes and drive ferroptotic cell death. RSL3-induced ferroptosis is caspase-independent and does not involve typical apoptotic pathways. Overexpression of GPX4 or treatment with iron chelators (e.g., deferoxamine) can rescue cells from RSL3-mediated death, confirming the specificity for iron-dependent, non-apoptotic pathways .

Evidence & Benchmarks

• RSL3 selectively induces ferroptosis in RAS-mutant and treatment-resistant prostate cancer cells, with IC₅₀ values in the low nanomolar range under standard in vitro conditions (37°C, 5% CO₂) (Ghoochani et al., 2021).
• In xenograft mouse models (athymic nude mice, BJeLR cells), subcutaneous administration of RSL3 at doses up to 400 mg/kg significantly reduced tumor volume without observable systemic toxicity (Ghoochani et al., 2021).
• RSL3-induced cell death is fully rescued by GPX4 overexpression or iron chelation (100 µM deferoxamine, 24 h), confirming specificity for ferroptosis pathways (Ghoochani et al., 2021).
• Combination of RSL3 with second-generation anti-androgens (enzalutamide or abiraterone, 10 µM) further suppresses tumor growth and migration in vitro and in vivo (Ghoochani et al., 2021).
• RSL3 is insoluble in water and ethanol but highly soluble in DMSO at ≥125.4 mg/mL; optimal storage is at -20°C with fresh solution preparation recommended (APExBIO).

For a systems biology approach to RSL3 and ferroptosis, see this article; the present review emphasizes translational and mechanistic benchmarks in oncology models.

Applications, Limits & Misconceptions

RSL3 is widely used to study oxidative stress, lipid peroxidation modulation, and ferroptosis signaling in cancer biology. Its synthetic lethality with RAS mutations makes it a valuable tool for investigating redox vulnerabilities in tumor cells (contrast: strategic blueprint article emphasizes translational applications). In preclinical models, RSL3 demonstrates robust growth inhibition and rapid induction of iron-dependent cell death, supporting its use in drug screening and mechanistic research (see also: mechanistic insights).

Common Pitfalls or Misconceptions

• RSL3 specifically targets GPX4; it is not a general ROS generator and does not directly induce apoptosis or necroptosis.
• Its activity requires the presence of iron; iron chelators or low-iron media can abolish RSL3-induced ferroptosis.
• RSL3 is not bioavailable orally and is not approved for clinical use; all applications are at the preclinical research stage.
• Solubility in aqueous buffers is poor; improper dissolution may lead to inconsistent dosing or assay results.
• Protect RSL3 solutions from prolonged storage at room temperature, which can cause compound degradation and reduced efficacy.

Workflow Integration & Parameters

For experimental use, RSL3 is provided by APExBIO (B6095) as a solid and should be dissolved in DMSO at concentrations of ≥125.4 mg/mL before dilution into culture media. Warming and sonication can enhance dissolution. Fresh preparations are recommended for reproducibility. Standard in vitro assays typically use 10–500 nM RSL3, with cytotoxicity observed within 6–24 hours in sensitive cell lines. For in vivo studies, subcutaneous administration up to 400 mg/kg has been well-tolerated in athymic nude mice. Appropriate controls include GPX4 overexpression, iron chelators, and assessment of non-apoptotic markers. For detailed experimental strategies, see this article, which decodes ferroptosis signaling beyond apoptosis-focused paradigms.

Conclusion & Outlook

RSL3 is a selective and potent tool compound for dissecting ferroptosis mechanisms in cancer biology. Preclinical studies highlight its efficacy in models with redox and iron metabolism vulnerabilities, underpinning its value for translational research. Ongoing work is expanding the therapeutic implications of ferroptosis induction, particularly in treatment-resistant and RAS-driven cancers. For product details and ordering, visit the RSL3 (glutathione peroxidase 4 inhibitor) page at APExBIO. As research progresses, RSL3 will remain central to modeling ferroptosis, benchmarking oxidative stress modulation, and advancing precision oncology approaches.